Jump to ContentJump to Main Navigation

Open Life Sciences: Topical Issue on Cancer Signaling, Metastasis and Target Therapy

  ◄ Back to journal



Jiacong (Jessica) You


Cancer signaling

Cancer signal transduction process is an effective way to react to external stimuli that eventually leads to specific biological effects. Great progress has been achieved in explaining the key signaling pathways in the development, growth and metastasis of cancer and great progress has been made in signaling pathways drug screening. Discoveries in cancer signaling help us to better understand the mechanisms of cancer development and progression. Knowing cancer signaling pathways we may specifically target them and improve significantly cancer therapeutics.

Cancer metastasis

Cancer metastasis is a basic feature of malignant tumor, and it is also the main reason for the failure of cancer treatment. Cancer metastasis occurs when genetically unstable cancer cells adapt to a tissue microenvironment that is distant from the primary tumor. This process involves both the selection of traits that are advantageous to cancer cells and the concomitant recruitment of traits in the tumor stroma that accommodate invasion by metastatic cells. Recent study advances promote our understanding of the origins and nature of cancer metastasis. For the clinical point, the study of tumor metastasis is still the focus of many studies.

Cancer target therapy

Cancer target therapy is a newly developed approach for cancer treatment. With the advantages of lower side effect and higher performance, this approach has become a critical focus of cancer research. In recent years the great progress in the research of therapeutic targets for cancer and the great development of new therapeutic drugs has been made. Also the current treatment of cancer has entered a new stage. Further development of basic research in cancer, better biotechnological development, better understanding of cancer occurrence and development processes will gradually allow identifying specific target molecules and will bring more change for cancer treatment in the future.


The authors are kindly invited to register at OLS paper processing system at: http://www.editorialmanager.com/openbiol and submit their contribution using a special track established for this Topical Issue (Cancer SMTT). All papers will go through the Open Life Sciences high standards, quick, fair and comprehensive peer-review procedure. Instructions for authors are available here. In case of any questions please contact Guest Editor or Managing Editor.

Submission deadline: April 30, 2016

As an author of Open Life Sciences Topical Issue Cancer SMTT on you will benefit from:

  • transparent, comprehensive and fast peer review managed by our esteemed Coordinating Editor
  • efficient route to fast-track publication and full advantage of De Gruyter Open e-technology
  • reduced Article Processing Charge
  • free language assistance for authors from non-English speaking regions